BAY-6672 is an orally active, potent and selective prostaglandin F receptor (FP-R, PTGFR) antagonist (IC50 = 11 nM against 3 nM PGF2?-induced calcium flux in hFP-R Chem-1 cells; IC50 = 12/18 nM against 3 μM PGF2α-induced KC/MCP1 production in NIH-3T3) with >420-fold selectivity over human prostaglandin receptors (PG-Rs) EP1-4, DP, CRTH2 and IP. BAY-6672 shows in vivo efficacy in a murine lung fibrosis model (3, 10, 30 mg/kg b.i.d. p.o.).
Orally active, potent and selective prostaglandin F receptor (FP-R, PTGFR) antagonist with in vivo efficacy in a murine lung fibrosis model.
Journal of medicinal chemistry, 63(20), 11639-11662 (2020-09-25)
Idiopathic pulmonary fibrosis (IPF) is a rare and devastating chronic lung disease of unknown etiology. Despite the approved treatment options nintedanib and pirfenidone, the medical need for a safe and well-tolerated antifibrotic treatment of IPF remains high. The human prostaglandin
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.